News

Imaging Endpoints is a founding sponsor of Immuno-Oncology 360 (IO360) and is proud to once again be a lead sponsor for the IO360 conference on February 26-28 in New York City. In addition to being in the exhibition hall with…   Read More

Imaging Endpoints is perhaps the most dynamic and fastest-growing company in the imaging CRO industry. We value our team members and offer a host of benefits designed to develop a positive work environment. We are actively recruiting for a variety…   Read More

Imaging Endpoints’ Chief Medical Officer Ron Korn will be presenting “New Imaging Technologies for Evaluation of Immune Response” at the 6th Annual Immuno-Oncology 360 conference Feb. 26-28 in New York City. To schedule a visit with our team on-site, contact…   Read More

We leverage the analysis of FDG-PET images to expand eligibility in clinical trials by providing a means to evaluate disease in patients who are otherwise non-assessable by RECIST. As an example, bone-only disease can be a leading reason for classification…   Read More

Virginia O’Malley, Imaging Endpoints’ Vice President and General Counsel was recognized as a finalist for the 2020 Arizona Corporate Counsel Award for the Technology Company category at a recent ceremony in Scottsdale. The award recognition was presented by AzBusiness magazine…   Read More

Imaging Endpoints announced today that the U.S. Patent and Trademark Office has issued Patent No. 10,332,634 – “Systems And Methods For Reliably Diagnosing Breast Cancer Using Quantitative Textural Analysis” to Imaging Endpoints’ and its inventor, Chief Medical Officer, Ron Korn,…   Read More

Imaging Endpoints Assists FORMA Therapeutics as Olutasidenib Demonstrates Positive Phase 1b/2 Results, Including Blood-Brain Barrier Penetration And Stable Disease In Patients With IDH1-Mutated Glioma. The Data Was Recently Presented at the 2019 Society for NeuroOncology Annual Meeting. WATERTOWN, Mass. –…   Read More

Imaging Endpoints is perhaps the fastest-growing imaging CRO (iCRO) in the industry. We are proud to celebrate our tenth consecutive year of impressive growth and contribution to our mission of Connecting Imaging to the CureTM. Client retention and leadership in…   Read More

Key Points Question Is adding cisplatin to nab-paclitaxel and gemcitabine treatment associated with increased overall survival and complete response potential among patients with metastatic pancreatic adenocarcinoma? Findings In this single-arm, phase 1b/2 clinical trial of 25 patients, the combination of…   Read More

TYME launched its multicenter randomized controlled pivotal stage of TYME-88-Panc trial for use of SM-88 in patients with third-line pancreatic cancer based on these clinical outcomes SM-88 is an oral, investigational cancer metabolism-based therapy that has demonstrated confirmed clinical responses…   Read More